Pharmaceuticals
News Releases
News releases related to oncology
2023
Pharmaceuticals
Otsuka's U.K. subsidiary Astex Has Third Approval Success in a Drug Discovery Collaboration - AstraZeneca's Truqap™ for the treatment of metastatic breast cancer approved in the U.S.
Pharmaceuticals
Otsuka and Astex announce that the European Commission has approved INAQOVI® (oral decitabine and cedazuridine) for the treatment of adults with newly diagnosed acute myeloid leukaemia
Pharmaceuticals
Astex Expands Drug Discovery Collaboration With MSD
2022
Pharmaceuticals
Announcement of Termination of Co-Development and Exclusive MarketingAgreements with Takara Bio for NY-ESO-1・siTCR® gene therapy candidate
Pharmaceuticals
European Medicines Agency commences review of oral fixed-dosecombination of decitabine and cedazuridine for the treatment ofadults with acute myeloid leukemia
Pharmaceuticals
Osaka University and Otsuka Pharmaceutical to Enter into an Exclusive License Agreement on New Anti-tumor Antibody
Pharmaceuticals
Otsuka Subsidiary to Receive Payment and Royalties from Approval in U.S. ofRadioligand Therapy for Metastatic Castration-Resistant Prostate Cancer- Out-licensed by ABX in Germany, an indirectly-owned subsidiary of Otsuka Pharmaceutical -
2021
Pharmaceuticals
Otsuka and Rebirthel Sign Licensing Agreement for iPSC-derived CAR-T / TCR-T Production Technology
Pharmaceuticals
Announcement of Termination of Co-Development and Exclusive Marketing Agreements with Takara Bio for Oncolytic virus HF10 and CD19-Targeted CAR Gene Therapies
Pharmaceuticals
Busulfex Injection 60mg Approved in Japan for Once-daily Administration in Pediatric Patients
2020
Pharmaceuticals
Otsuka and its subsidiary Astex announce results of phase 3, ASTRAL-2 and ASTRAL-3 trials of guadecitabine in patients with previously treated AML and MDS/CMML
Pharmaceuticals
Otsuka announces simultaneous regulatory approvals by U.S. FDA and Health Canada of INQOVI®, an oral hypomethylating agent (HMA) therapy for MDS and CMML
Pharmaceuticals
Clinical program for NY-ESO-1/siTCRTM gene therapy candidate receives designation in Japan as Orphan Regenerative Medicine
Pharmaceuticals
Otsuka's Busulfex Receives Additional Indication in Japan as a Conditioning regimen Prior to Autologous Hematopoietic Stem Cell Transplantation for Malignant Lymphoma
2019
Pharmaceuticals
Otsuka and Taiho Announce that Taiho Will Commercialize Two of Astex Pharmaceuticals' Drug Candidates in North America
Pharmaceuticals
Otsuka and its Subsidiary Astex Pharmaceuticals, Inc. Announce Positive Results from a Phase III Clinical Trial of Anticancer Candidate ASTX727
Pharmaceuticals
Erdafitinib Receives Regulatory Approval in U.S.
Pharmaceuticals
Designation Description Change of NY-ESO-1・siTCRTM gene therapy product under "SAKIGAKE Designation System"
2018
Pharmaceuticals
Busulfex Injection 60mg Approved in Japan for Once-Daily Administration in Adults
Pharmaceuticals
Otsuka and Astex announce results of the phase 3 ASTRAL-1 study of guadecitabine (SGI-110) in treatment-naïve AML patients ineligible to receive intense induction chemotherapy
Pharmaceuticals
Otsuka enters agreement with Takara Bio for co-development and sales rights in Japan to NY-ESO-1 siTCRTM and CD19 CAR gene therapies
2017
Pharmaceuticals
Otsuka to Invest in Megakaryon Corporation, with the Aim to Advance Commercialization of iPS-cell-derived Platelet Preparations
Pharmaceuticals
Ribociclib (LEE011) Receives Regulatory Approval in U.S. as a First-Line Treatment for HR+/HER2- Advanced Breast Cancer with an aromatase inhibitor
2016
Pharmaceuticals
Otsuka Signs Japan-Exclusive License Agreement with Takara Bio for the Investigational Cancer Treatment HF10, an Oncolytic Virus
Pharmaceuticals
ICLUSIG® Tablets 15 mg Now Available in Japan for Patients with Chronic Myeloid Leukemia and Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia
Pharmaceuticals
Positive Phase III Clinical Trial Results for Ribociclib (LEE011), an Investigational Compound for Advanced Breast Cancer in Development by Major Pharmaceutical Company under a Research Collaboration with Otsuka's Subsidiary Astex Pharmaceuticals
Pharmaceuticals
ICLUSIG® Tablets 15 mg Approved in Japan for Patients with Chronic Myeloid Leukemia and Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia
Pharmaceuticals
Otsuka's U.S. Subsidiary Astex Pharmaceuticals Enters Clinical Trial Collaboration to Explore the Potential of Combining Guadecitabine (SGI-110) with Atezolizumab in the Treatment of Acute Myeloid Leukemia
Pharmaceuticals
Otsuka and ARIAD Announce New Drug Application for Ponatinib Submitted in Japan for the Treatment of Refractory Leukemia
2014
2012
Pharmaceuticals
Kyowa Hakko Kirin Returns to Otsuka Pharmaceutical the Rights to Develop and Market Busulfex®, for Use As a Part of Conditioning Regimen Prior to Hematopoietic Progenitor Cell Transplantation, in Japan and in Asian Countries & Regions
Pharmaceuticals
Otsuka Pharmaceutical and Kyowa Hakko Kirin announce strategic alliance in the fields of diabetes and oncology
2011
Pharmaceuticals
Anti-cancer agent "Sprycel® 20mg Tablets and Sprycel® 50mg Tablets (dasatinib)" approved as the first-line treatment of chronic myeloid leukemia-A new treatment option for newly-diagnosed CML patients-
Pharmaceuticals
Otsuka Announces Initiation of Phase I Clinical Trial for Therapeutic Cancer Vaccine OCV-105
Pharmaceuticals
Otsuka Announces Initiation of Phase II Clinical Trials for Angiogenesis Inhibitor OCV-101
2010
Pharmaceuticals
Starting co-promotion of the anti-cancer agent SPRYCEL® Tablet 20mg and SPRYCEL® Tablet 50mg (dasatinib) in Japan
Pharmaceuticals
The results of a subset analysis of Japanese patients from the DASISION trial comparing SPRYCEL® (dasatinib) with imatinib in the treatment of newly diagnosed Philadelphia chromosome positive chronic myelogenous leukemia.
Pharmaceuticals
Follow-Up Results from Study Comparing SPRYCEL® (dasatinib) to Imatinib in First-Line Treatment of Adults with Ph+ CP-CML Demonstrate Improved Response Rates Consistent with 12 Month Data*1
Pharmaceuticals
FDA Approves SPRYCEL® (dasatinib) as Treatment for Adult Patients with Newly Diagnosed Ph+ Chronic Myeloid Leukemia in Chronic Phase
Pharmaceuticals
OTSUKA OPENS FIRST OFFICE IN CANADA Important Milestone for Growing North American Pharmaceutical Operations
Pharmaceuticals
SPRYCEL® (dasatinib) Receives FDA Priority Review for the Treatment of Adult Patients with Newly Diagnosed Chronic Myeloid Leukemia (CML) in Chronic Phase
Pharmaceuticals
GW and Otsuka Agree Three Year Extension to Global Cannabinoid Research Collaboration
Pharmaceuticals
Four-Year Follow-Up Data for SPRYCEL® (dasatinib) Demonstrate 82 Percent Overall Survival in Patients with Chronic Myeloid Leukemia Who Failed Gleevec®*
Pharmaceuticals
SPRYCEL® (dasatinib) Demonstrates Superior Confirmed Complete Cytogenetic Response Rates Compared to Gleevec®* in Study of Adult Patients with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase
Pharmaceuticals